Dimitry Nuyten

Direttore Tecnico/Scientifico/R&S presso ARCUS BIOSCIENCES, INC.

Patrimonio netto: 203 569 $ in data 30/04/2024

48 anni

Health Technology

Consumer Services

Posizioni attive di Dimitry Nuyten

Società	Posizione	Inizio	Fine
ARCUS BIOSCIENCES, INC.	Direttore Tecnico/Scientifico/R&S	01/08/2022	-

Società	Posizione	Inizio	Fine
NEKTAR THERAPEUTICS	Direttore Tecnico/Scientifico/R&S	19/07/2021	01/04/2022
PFIZER, INC.	Corporate Officer/Principal	01/07/2013	01/03/2019
BRISTOL-MYERS SQUIBB COMPANY	Direttore Tecnico/Scientifico/R&S	01/03/2008	01/06/2013
CHINOOK THERAPEUTICS, INC.	Direttore Tecnico/Scientifico/R&S	22/04/2019	-

University of Groningen	Doctorate Degree
University of Amsterdam	Doctorate Degree

Distribuzione geografica

Stati Uniti	6
Paesi Bassi	3

Posizioni

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	2
Corporate Officer/Principal	1

Settori

Health Technology	6
Consumer Services	3

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	4
PFIZER, INC.	Health Technology
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
NEKTAR THERAPEUTICS	Health Technology
ARCUS BIOSCIENCES, INC.	Health Technology

Aziende private	1
Aduro BioTech, Inc. Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.	Health Technology

Aziende private

Health Technology